Nonprofit group gains right to develop rilpivirine for HIV prevention

09/25/2013 | Genetic Engineering & Biotechnology News

PATH, an international nonprofit organization, has been granted rights through a deal with Janssen R&D of Ireland to develop an injectable form of the HIV-1 drug rilpivirine as a potential preventive treatment for HIV. Backed by the Bill & Melinda Gates Foundation, PATH plans to carry out prophylaxis trials in partnership with the HIV Prevention Trials Network and the NIH's AIDS division. PATH and Janssen could enter a late-stage development deal based on the results of the trial.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC